005500 — Samjin Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapSuper Stock

Annual income statement for Samjin Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	235,165	250,070	274,032	292,129	308,350
Cost of Revenue
Gross Profit	110,516	117,832	117,734	116,681	128,967
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	202,832	216,120	250,065	271,628	276,822
Operating Profit	32,333	33,951	23,967	20,501	31,528
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	32,830	34,911	25,226	15,557	43,642
Provision for Income Taxes
Net Income After Taxes	27,879	28,404	21,901	18,906	39,233
Minority Interest
Net Income Before Extraordinary Items
Net Income	27,879	28,404	21,894	18,908	39,233
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	27,879	28,404	21,894	18,908	39,233
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2,239	2,238	1,640	1,450	3,123
Dividends per Share